MedTrace Logo

Safety and Efficacy of Long-term Somatropin Treatment in Children

NCT01543867 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5442

Last updated 2015-03-30

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this study is to evaluate safety during the long-term use of somatropin (Norditropin®) in children as well as efficacy on change in height. A subgroup of children small for their gestational age is included.

Conditions

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Foetal Growth Problem
  • Small for Gestational Age
  • Genetic Disorder
  • Turner Syndrome
  • Growth Disorder
  • Idiopathic Short Stature

Interventions

DRUG

somatropin

Prescribed at the discretion of the treating physician according to product labelling

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543867 on ClinicalTrials.gov